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Abstract 
RNA interference (RNAi) therapy is an emerging class of biopharmaceutical that has 
immense potential in cancer medicine. RNAi medicines are based on synthetic 
oligonucleotides that can suppress a target protein in tumour cells with high specificity. This 
review explores the attractive prospect of using RNAi as a radiosensitizer by targeting the 
DNA damage response. There are a multitude of molecular targets involved in the detection 
and repair of DNA damage that are suitable for this purpose. Recent developments in 
delivery technologies such nanoparticle carriers and conjugation strategies have allowed 
RNAi therapeutics to enter clinical trials in the treatment of cancer. With further progress, 
RNAi targeting of the DNA damage response may hold great promise in guiding radiation 
oncology into the era of precision medicine. 
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Background 
Radiation therapy is a well-established treatment modality for cancer with an important role 
in the curative and palliative setting. Approximately 50% of all cancer patients will benefit 
from receiving radiotherapy at some point in their illness (1). In most cancer types the 
tumour control rate improves with an increasing dose of radiation (2,3). However, radiation 
causes both early and late reactions in the surrounding normal tissue (4). This leaves a 
narrow therapeutic window where the challenge is to deliver an adequate radiation dose 
for tumour control without causing overt toxicity (5). 
The introduction of radiosensitizing agents in combination with external beam radiotherapy 
has greatly improved the efficacy of radiation treatment. The most common agents are 
cytotoxic chemotherapy agents such as cisplatin and 5-fluorouracil which have been shown 
to improve tumour control and patient survival outcomes when combined with 
radiotherapy (6–8).  However, due to the non-discriminatory distribution of these highly 
cytotoxic agents they also sensitise normal tissue to radiation leading to greater toxicity (9). 
RNA interference (RNAi) therapies offer an alternative approach to radiosensitization. The 
mechanism of action of radiation therapy is by causing preferential DNA damage to the 
tumour by exploiting differences in DNA damage response in cancer and normal cells. By 
precisely targeting the response to this DNA damage with RNAi, it may be possible to 
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achieve potent radiosensitization whilst minimising the adverse effects on normal tissues 
(10). The fundamentals of this technology are developing in the preclinical setting with 
momentum building for translation to the clinic (11). This review will focus on the use of 
RNAi to target the DNA damage response for the purpose of radiosensitisation.   
 
Mechanisms of RNA Interference 
RNAi with therapeutic oligonucleotides is a hugely promising technology in cancer 
treatment (12,13). The system uses human genomic data to design and synthesize 
oligonucleotides that can be introduced into the cell of interest to silence specific genes. 
There is great potential in targeting and disabling pathways in tumours that are responsible 
for resistance to radiation, thereby improving the overall efficacy of radiation therapy.  
RNAi oligonucleotides are small, non-coding RNA molecules that are usually 20-25 base 
pairs in length which come in several classes. Antisense oligonucleotides (ASO) are the 
earliest developed and simplest in structure and are usually single stranded RNA molecules 
(14). MicroRNA (miRNA) are endogenously occurring RNA, usually with a short hairpin 
structure, and form the basis for the manufacture of synthetic mimics (15). However, the 
most widely used form of RNAi are short interfering RNA (siRNA) which are double stranded 
RNA that can be designed and synthetically produced and are valued for their specificity and 
efficacy (16). 
The mechanism of action of these oligonucleotides relies upon the highly efficient 
intracellular processing of RNAi present in mammalian cells. The RNAi oligonucleotide is 
introduced to the cell as a single or double stranded complex (Figure 1). Once in the 
cytoplasm it is loaded into a set of proteins known as the RNA-inducing silencing complex 
(RISC) (17). The RISC complex removes the passenger strand of the RNAi if present allowing 
the remaining single strand to bind to complementary mRNA sequences. Matching mRNA 
that binds undergoes endonucleolytic cleavage and is degraded, leading to downregulation 
of the corresponding protein expression.  
The main strength of RNAi is that in theory any protein within the cell with a known mRNA 
sequence becomes a druggable target (18). This also allows for a highly specific knockdown 
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of the corresponding protein. Moreover, because a single RISC complex will destroy multiple 
mRNA targets, nanomolar or even picomolar concentrations of siRNA can effectively 
knockdown proteins for days to weeks (17,19). These features of RNAi can be exploited for 
radiosensitisation by targeting the complex machinery of the cellular DNA damage 
response.  
 
Targeting the DNA Damage Response 
Clinical radiotherapy uses high-energy ionising radiation, which is delivered with highly 
conformal techniques to the tumour (4). The biological effects of ionising radiation are 
caused by damage to DNA which if unable to be repaired leads to the death of the tumour 
cell by apoptosis or mitotic catastrophe (20). Targeting this mechanism of radiotherapy may 
be an effective method of enhancing its effect on tumours. Central to this strategy are the 
inherent features of cancer cells of a greater burden of endogenous DNA damage and  
abnormalities in the cellular DNA damage response (DDR).  
 
The DDR is a complex, sensitive and interconnected pathway (Figure 2), broadly consisting 
of sensors, transducer, effector and mediator proteins which undergo numerous post-
translational modifications – particularly phosphorylation, ubiquitylation and sumoylation – 
to trigger a variety of cellular responses (21,22). The DDR has an important role in cancer 
progression because its dysregulation leads to higher mutation rates, genomic instability, 
and enhanced intra-tumour heterogeneity (21,22). The differences between DDR pathways 
in normal cells and cancer cells are an attractive source of targets to be exploited by RNAi 
therapies.  The genomic instability combined with rapid cell turnover leaves cancer cells 
highly reliant on the DDR (23). Additionally, most cancer cells will have lost one or more 
DDR pathways leading to a greater dependency on the remaining pathways (24). Hence, the 
combination of radiation induced DNA damage whilst simultaneously using RNAi to disable 
the remaining functioning DDR pathways leads to an overwhelmingly and lethal amount of 
DNA damage to the tumour.  
 
Although the DNA damage response relies heavily on post-translational modifications for 
signal transduction, depletion of a number of key molecules has been shown to effectively 
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radiosensitise cells both in vitro and in vivo. The selection of RNAi targets in the DDR 
pathway is key to the success of this strategy. Due to the breadth of the DNA damage 
response, we will focus on components involved in double-strand break repair, because of 
its major role in ionizing–radiation induced cell death (25).  Double-strand breaks (DSB) are 
the most deleterious of DNA-lesions, and a single break is sufficient to induce cell death. 
DNA double-strand breaks are repaired via one of two main pathways: Non-Homologous 
End-Joining (NHEJ) or Homologous Recombination (HR). 
 
Targeting Non-Homologous End-Joining 
NHEJ is the major DSB repair pathway that is engaged to repair radiation-induced breaks 
(26). It can occur at all stages of the cell cycle, and relies on ligation of the broken DNA ends, 
with or without additional end processing. NHEJ begins with the binding of Ku70/Ku80 
heterodimer, flanking each broken end of the genetic insult and forming a platform for the 
binding of the DNA-dependent Protein Kinase catalytic subunit (DNA-PKcs). Together, 
Ku70/80 and DNA-PKcs form the DNA-PK holoenzyme, which can self-activate via 
autophosphorylation, as well as phosphorylate a number of downstream targets involved in 
signalling and repair of the break (27,28). In mechanisms which will not be discussed in 
detail here, additional proteins may then be engaged to process the break ends to render 
them amenable for joining, prior to final ligation of the broken DNA ends by the Ligase 
IV/XRCC4/XLF complex (26). 
 
The most attractive targets in the NHEJ pathway for radiosensitisation are of the obligate 
initial and final stages of this process (29). As an important initial step in sensing the DNA 
break, many studies have investigated the effects of depletion or inactivation of DNA-PKcs. 
The radiosensitivity conferred by DNA-PKcs depletion or loss stems from its critical role in 
the NHEJ pathway in recruiting and phosphorylating numerous repair factors and as an 
important kinase that shares many phosphorylation targets with ATM. Interestingly, the 
ways in which DNA-PK loss sensitises to radiation may be multifaceted. Depletion of DNA-
PKcs by siRNA leads to pronounced radiosensitivity in multiple human cell lines, leading to 
G2/M arrest and impeded mitotic progression. Interestingly, this effect was more 
pronounced with use of the DNA-PK inhibitor NU7441, which more severely impeded DDR 
signalling(30). Delivery of siRNA targeting DNA-PKcs in vitro with a commercial liposomal 
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method has been shown to reduce the capacity for restitution of radiation-induced 
interphase chromosome breaks and increase the yield of acentric chromosome fragments at 
post-irradiation mitosis. The result was an increase in radiosensitivity, particularly in p53-
mutant lymphoblast-derived cells, which lack functional G1/S checkpoint and exhibited a 2-
fold increase in radiosensitivity (31). Similarly, non-replicative adenovirus mediated delivery 
of short hairpin RNA (shRNA) to target DNA-PKcs in HCT116 colorectal cells in vitro 
demonstrated radiosensitisation. The strategy was initially not successful in vivo with a 
murine xenograft model due to poor transfection, but by introducing a conditionally 
replicative adenovirus the transfection issues were overcome with potent in vivo 
radiosensitivity demonstrated with DNA-PKcs knockdown  (32).  
 
The Ku proteins could also be potential therapeutic RNAi targets as critical mediators of 
early NHEJ. Currently no small molecule inhibitors have been demonstrated to have 
inhibitory activity against these proteins. However, multiple studies have demonstrated 
radiosensitisation upon Ku loss or depletion. Ku70-deficienct embryonic stem cells are 
sensitised to ionizing radiation, and RNAi-mediated depletion by lentivirus in mammary cells 
conferred radiosensitivity (33,34). A haemagglutinating virus of Japan envelope vector was 
used to deliver siRNA targeting Ku80 in A549 and H1299 lung carcinomas and when 
irradiated demonstrated markedly higher gamma-H2AX foci following DNA damage by IR, 
indicative of greater DNA damage. Moreover, tumour xenografts using these lines and 
treated with radiation  exhibited greater cytoreduction and slower regrowth compared to 
radiation alone, illustrating effectiveness of this strategy in vivo (35). An alternate strategy 
to induce radiosensitisation through targeting the NHEJ pathway would be to inactivate the 
final ligation step of this process which is reliant on the Ligase IV and XRCC4 molecules. 
Targeting of XRCC4 protein and its co-factor XLF with siRNA in U-2OS osteosarcoma cells led 
to potent radiosensitisation (36). Similarly, knockout of Ligase IV protein in multiple cultured 
cell lines or in mice (37,38) causes pronounced radiosensitisation, suggesting its use also as 
a radiosensitisation target.  
 
Targeting Homologous Recombination  
In contrast to NHEJ, Homologous Recombination (HR), is a high-fidelity repair pathway 
active primarily in the S/G2 phase of the cell cycle, where the sister chromatid can act as a 
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template for repair. In brief, HR begins with the sensing of the DNA break by the Mre11-
Rad50-NBS1 complex. Following the initial sensing of the break, resection occurs by a 
number of proteins beginning with Mre11, CTIP and including Exo1 and DNA2 to form long 
3’ single-stranded DNA intermediates which are coated by the Replication Protein A 
complex (39,40). In subsequent steps, RPA is replaced by Rad51, mediated by BRCA2, BRCA1 
and additional proteins to form the synaptic filament. Rad51-coated ssDNA is then able to 
invade the sister chromatid, which is used as a template for repair (40).  
 
As a core component of HR, Rad51 has been the subject of multiple efforts to develop small 
molecule inhibitors (41–43). Many cancers have been shown to overexpress Rad51, and its 
overexpression inversely correlates with radiosensitivity (41). A commercial liposomal 
vector was used to transfect glioma cells with antisense oligonucleotides against RAD51 and 
was found to significantly enhance the radiation induced cell kill compared to control cells. 
In a orthotopic murine glioma model, the combination of RAD51 antisense oligonucleotides 
and radiation led to extended survival times of glioma-bearing mice (44). 
 
Another method under intense investigation over recent years has exploited HR pathway 
deficiency in cancer cells for therapeutic gain using  inhibitors  of PARP proteins (45). The 
PARP proteins are a family of poly-ADP ribosylation factors, which post-translationally 
modify a number of proteins by PARylation - the synthesis of PAR chains onto substrate 
proteins (46). When a single-strand DNA break occurs, PARP proteins are one of the earliest 
responders, binding to DNA and PARylating downstream proteins before auto-PARylation 
facilitating their release from DNA (47). Single-strand DNA breaks are one of the most 
common genetic lesions, occurring thousands of times in each cell every day, and PARP 
proteins are critical factors in their repair (48). However, if single-strand breaks are not 
appropriately repaired, they can convert to double-strand breaks during S phase. Recently 
developed small molecule PARP inhibitors allow trapping of PARP at the site of breaks, 
promoting this occurrence, and resulting in the formation of double-strand breaks. In cancer 
cells which have inherent deficiencies in HR (such as occurring in BRCA1/2 deficient breast 
and ovarian cancers), the treatment with PARP inhibitors exploits this deficiency to cause 
death in the cells, a concept known as synthetic lethality  (47,49,50). PARP inhibitors 
represent one of the rare successful cases of small molecule DNA repair inhibitors with 
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success in the clinic. However, like with other small molecule inhibitors, development of 
acquired resistance to PARP inhibitors was ubiquitous, hampering the duration of response, 
and overall survival benefit in clinic (51–53). However, several combination approaches are 
being investigated to overcome resistance to PARP inhibitors, including the combination 
with radiotherapy. PARP inhibitors are being tested in clinical trials for synergism with 
radiation therapy, not only in HR-deficient cancers, but also for head and neck cancers(54), 
and glioma(55). Excitingly, this success may open additional avenues for triple-combination 
therapies, where the tumour could be rendered HR deficient by RNA, and treated with a 
single or combination therapy of PARP inhibitor and radiation therapy.  
 
Targeting DNA-damage Response Signalling 
The HR and NHEJ repair pathways rely on the initial detection of DNA damage. Ataxia-
Telangiectasia Mutated (ATM), named after the protein mutated in the genetic disorder 
Ataxia-Telangiectasia (A-T), is one of the earliest responders to DNA DSBs, and is a kinase 
belonging to the same family as DNA-PK (56). Patients with A-T and derived cell lines from 
these patients are exquisitely radiosensitive (57,58). ATM works by co-operating with a 
trimeric protein complex composed of MRE11-RAD50-NBS1 (59). The importance of these 
proteins in the DDR is illustrated by their phosphorylation of more than 700 downstream 
targets in response to DNA damage (60). With its position at the apex of DDR signalling and 
repair, it represents an ideal target for radiosensitisation.  
 
Efforts to target ATM in the clinic with small molecule inhibitors have been relatively 
unsuccessful. ATM inhibitors often have off-target effects with other PI3-kinases, are not 
useful at concentrations required for treatment and have been shown to cause a 
gastrointestinal syndrome after total body irradiation in preclinical models (61,62). The use 
of exogenously delivered plasmids encoding siRNA targeting ATM and a related protein ATR 
was found to be a potent radiosensitizer in DU-145 and PC-3 cells in vitro. One study whilst 
investigating the effects of hyperthermia showed siRNA mediated-downregulation of 
MRE11 in colon adenocarcinoma cells induces radiosensitisation in vitro. Another study 
targeted another protein of the trimeric complex, NBS1 in H1299 lung cancer cells leading to 
increase radiosensitivity in vitro (63). Furthermore, RNAi targeting of ATM and the Mre11-
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Rad50-NBS1 complex has been shown to be effective at sensitising prostate, colon and lung 
cancer cells to radiation (61,63,64).  
 
Downstream of the ATM and ATR kinases: targeting CHK1 and CHK2 
Finally, the checkpoint kinases serve as important downstream transducers of the DDR and 
act predominantly downstream of the ATR and ATM kinases (60,65). Checkpoint kinases 
serve to halt the cell cycle in response to DNA damage, until the damage is appropriately 
addressed (via repair or induction of cell death) (66). Cancer cells often have inherent 
defects in p53-dependent G1/S DNA damage checkpoint, one of the most commonly 
mutated tumour suppressor gene in cancers, resulting in an increased dependency on the 
remaining functional checkpoint machinery. A lentivirus-delivered shRNA targeting Chk1 in 
human glioblastoma stem-like cells in combination with radiation increased the apoptosis 
rate, decreased the degree of G2/M arrest and was associated with increased 
radiosensitivity (67). Targeting of CHK1 by RNAi in particular warrants further investigation 
due to the failure of inhibitors in the clinic (68).  
 
Risks and Rationale of Targeting the DDR with RNAi 
 
RNAi targeting of DDR however is not without risk of toxicity. From clinical experience with 
small molecule DDR inhibitors we know that this approach can have associated adverse 
effects including myelosuppression(69), cardiac toxicity (70), gastrointestinal toxicity (61) 
and neurotoxicity (71) and rarely can cause second malignancies such as acute myeloid 
leukaemia (72). The RNAi technology has its own inherent toxicities such as off-target 
effected caused by cross-hybridisation with unintended transcripts that contain partial 
identity to the RNAi sequence leading to unintentional silencing of other protein(73). RNAi 
can also stimulate an immune response and in some cases can oversaturate the RISC 
complex (74,75).  Many of these can be minimised with sequence optimisation and 
oligonucleotide structure modification.  
 
The rationale in targeting the DDR is validated by several small molecule inhibitors which 
are the subject of pre-clinical and clinical trials (22,76). However, to date most of these 
drugs have not been successfully adopted in clinical practice. They remain costly to develop, 
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can have poor bioavailability and can have off-targets in vivo with associated toxicity. Hence 
these targets may be suited to targeting with RNAi, with the added benefit that multiple 
RNAi targets could be easily combined for therapeutic advantage.  
 
Delivery Technology for RNA Interference 
Despite the abundance of targets for radiosensitization the clinical translation of RNAi for 
therapy poses some significant challenges (Figure 3) (77). RNAi oligonucleotides are not 
stable in circulation due to the presence of ribonucleases with more than 99% degrading in 
human blood within minutes of incubation (78). Their size is small enough to be rapidly 
cleared through the kidneys but large enough to be targeted by the reticuloendothelial 
system (79). Their polyanionic and hydrophilic properties leads to difficulty in penetrating 
the phospholipid bilayer making up the cell wall (80). Even once taken into the cell, they are 
entrapped in endosomes and only a small fraction are released into the cytoplasm to be 
therapeutically active (81).  
 
However, delivery technology for RNAi has been rapidly developing to meet these 
challenges with examples including viral vectors, nanoparticles and aptamers. A 
comprehensive review of delivery technologies for RNA interference is outside the scope of 
this article, but there are several recent reviews on the topic (82–85). To our knowledge, 
there are currently no clinical trials investigating the use of RNAi delivery in combination 
with radiotherapy. However, the following selection of RNAi delivery technologies may act 
as a gateway to future trials of RNAi in combination with ionising radiation. 
 
One of the earliest delivery methods was using viral constructs that encapsulate a modified 
genome that carries a therapeutic gene cassette in place of the original viral genome (86). 
These viral particles are incapable of replicating and instead only function to infect a cell 
leading to the expression of the therapeutic genetic information. The most common viral 
vectors are adenoviruses (87) and we have already provided some examples in the previous 
sections of proteins responsible that have been targeted successfully with this strategy in 
the preclinical setting (32,63,88). Examples outside of the DDR pathway include using 
adenovirus-mediated strategies for radiosensitisation targeting matrix metalloproteinase-2 
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(MMP-2) in glioma (89), anti-apoptosis protein survivin in lung cancer (90) and the Mcl-1 
gene in pancreatic carcinomas (91). There are some barriers to the clinical translation of 
adenovirus vectors including the potential for inflammatory, immunogenic and mutagenic 
effect, which makes them a safety risk for translation to humans (86–88). Viral vectors also 
have a high cost of production, which can be a barrier when scaling up manufacturing (92). 
Nevertheless, oncolytic adenoviruses has been used as non-RNAi gene therapy vector in 
combination with radiotherapy in a Phase II clinical trial in intermediate risk prostate cancer 
(93).  
 
Nanoparticle delivery vehicles are another promising method for RNAi delivery (94). 
Nanoparticles are clusters of atoms of molecules ranging usually from 1 nm to almost 1000 
nm in size and can be composed of lipids, polymers, proteins and inorganic compounds. 
RNAi nanoparticle platforms are designed to encapsulate and protect the oligonucleotide 
cargo from degradation thereby greatly enhancing the delivery to the tumour. In addition 
they benefit from the enhanced permeability and retention (EPR effect), a biophysical 
phenomenon where abnormal vasculature of solid tumours with wide fenestrations allows 
molecules within the nanoparticle size range to preferentially accumulate within solid 
tumours and be retained there by high lymphatic pressures (95). The result is a higher 
concentration of the radiosensitiser within the tumour and lower concentration within the 
normal tissue (Figure 4). These advantages have led to a number of preclinical studies. Iron 
oxide nanoparticles coated with polyethylene glycol (PEG) and polyethyleneimine (PEI) were 
used to delivery siRNA against the DNA base excision repair protein Ape1 in 
medulloblastoma and ependymoma cells as a radiosensitiser(96). Similarly, a PEG-PEI 
copolymer was used to deliver siRNA against sCLU in a MCF-7 breast cancer cell line with 
evidence of radiosensitisation (97). 
 
A number of nanoparticles are approved for clinical use in oncology including liposomal 
doxorubicin, liposomal irinotecan and albumin-bound paclitaxel (98). Nanoparticles for RNAi 
delivery are being investigated in clinical trials (Table 1). Lipid-based nanoparticles are the 
mainstay of RNAi cell transfections for life science research with a number of commercially 
available formulations (99). Early nanoparticles had difficulty travelling beyond the liver 
leading to interest in using cationic liposomes to deliver siRNA to sensitize hepatoma cells to 
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radiation in vitro and in vivo (100). However, adaptation of liposomal delivery vehicles with 
polyethylene glycol (PEG) to reduce liver accumulation and fusogenic elements (101) to 
enhance cellular uptake have led to platforms like Atu027 developed by Silence 
Therapeutics, with evidence of efficacy in clinical trials (69,102). Another highly novel, 
recently developed RNAi nanoparticle delivery platform is a system of bacterially derived 
minicells each approximately 400 nm in diameter (103). These non-viable particles are 
produced by de-repressing polar sites of cell division in bacteria and can be loaded with 
RNAi oligonucleotides (104). They are coated with bispecific antibodies (BsAbs), which allow 
them to be targeted to a receptor that is overexpressed on the cancer cell (105). There are 
multiple preclinical studies to deliver siRNA and miRNA to tumour in vivo (106–108) and 
Phase 1 clinical trial in malignant mesothelioma deliver miR-16-based mimic microRNA were 
effective stabilising tumour growth in the majority of these patients. Even with these 
advances the challenges of nanoparticle delivery of RNAi beyond the liver(83) have not been 
overcome completely and clinical toxicity is unique and known to be present for each of the 
platforms(109) without being fully elucidated in clinical trials. Thus further work remains in 
developing nanoparticle delivery of RNAi as a monotherapy and in combination with 
radiotherapy. 
 
Lastly, developments in RNAi conjugates are being explored as a method of delivery (110). 
Advances in chemical modifications to RNAi oligonucleotides have enhanced their resistance 
to serum nucleases reducing the need for protective carriers such as nanoparticles 
(111,112). This allows conjugation with molecules such as antibodies and aptamers that 
allow active targeting to the intended tissue. Conjugation with monoclonal antibodies have 
been shown to effective in targeting siRNA to overexpressed tumour surface antigens (113). 
Aptamers  are oligonucleotides designed through a special selection process that function 
comparably to traditional antibodies, and are especially suited to this purpose (114). 
Aptamer/siRNA chimeras have the ability to target cellular receptors, promote uptake and 
deliver the siRNA payload (81). An aptamer-siRNA chimera was used to target the DDR 
pathway in prostate cancer. This approached used anti-DNA-PKcs siRNA with an aptamer 
targeting PSMA, a protein which is overexpressed in prostate cancer cells (115). It was 
shown to effectively deliver the siRNA in murine xenograft model leading to downregulation 
of DNA-PKcs and resulting in radiosensitisation of the tumour (116).  
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Conclusion and Future Directions 
The field of radiation oncology has experienced a quantum leap in technology with 
advances in imaging, dosimetric planning and treatment delivery (117). However, progress 
in the application of cancer biology to clinical radiotherapy has been much slower. Though 
conventional cytotoxic agents are associated with better outcomes, this comes at the cost 
of indiscriminate toxicity to normal tissue (118). The recent revolution in targeted 
constructs and immunotherapies may provide many opportunities for combination with 
radiation, however these agents are not designed with the purpose of being radiosensitizers 
(119). 
 
Gene therapy with RNAi holds great promise in combination with radiotherapy. There is a 
clear abundance of molecular targets in the DNA damage response pathway that can result 
in dramatic radiosensitisation in tumours. Although challenging to implement, the major 
attraction of siRNA-based drugs is that any of these genes may be targeted, which may 
otherwise not be possible with small molecule or protein based drugs. It also opens the 
exciting possibility of using multiple siRNAs targeting different pathways simultaneously 
silencing several genes responsible for radioresistance and leading to an even more potent 
effect.  
 
The challenge with RNA interference remains in the delivery. However, progress is being 
made with increasingly robust delivery platforms being developed to safely and efficiently 
deliver the RNAi payload to the cancer cells. This approach would take advantage of 
decades of radiobiology research on the DNA damage response to be applied in a way that 
has a direct clinical impact. RNA interference may aid in the development of truly 
personalised medicine in radiation oncology. 
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Table 1 Recent clinical trials of RNA interference therapeutics for cancer treatment 
Indications Name 
Delivery 
Route 
Target 
Delivery 
System 
Development 
Phase 
Clinical Trial 
Number 
Advanced solid 
tumors 
siRNA-
EphA2-
DOPC 
Intravenous 
(I.V.) injection 
EphA2 
Lipid-based 
nanoparticles 
Phase I, 
Recruiting 
NCT01591356 
Advanced solid 
tumors 
Atu027 I.V. infusion PKN3 
Lipid-based 
nanoparticles 
Phase I, 
completed 
NCT00938574 
Pancreatic 
ductal 
adenocarcinom
a; Pancreatic 
cancer 
siG12D 
LODER 
Intratumoral 
implantation 
KRASG1
2D 
LODER polymer 
Phase I, 
completed 
NCT01188785 
Primary or 
secondary liver 
cancer 
TKM-
080,301 
Hepatic intra-
arterial 
injection 
PLK1 
Lipid-based 
nanoparticles 
Phase I, 
completed 
NCT01437007 
METAVIR F3–4 
ND-L02-
s0201 
I.V. injection HSP47 
Lipid-based 
nanoparticles 
Phase I, 
completed 
NCT02227459 
Solid tumors; 
multiple 
myeloma; non-
Hodgkin’s 
lymphoma 
DCR-
MYC 
I.V. infusion MYC 
Lipid-based 
nanoparticles 
Phase I, 
terminated 
NCT02110563 
Cancer; solid 
tumour 
CALAA-
01 
I.V. injection RRM2 
Cyclodextrin-
containing 
polymer 
Phase I, 
terminated 
NCT00689065 
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Neuroendocrin
e tumors; 
adrenocortical 
carcinoma 
TKM 
080301 
I.V. infusion PLK1 
Lipid-based 
nanoparticles 
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Figure 1 Mechanism of RNA interference from exogenous siRNA 
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Figure 2 DNA Double-strand break repair Double-strand breaks can be repaired by two 
major pathways: Non-homologous end-joining or Homologous Recombination. 1. Non-
homologous end-joining begins with the binding of the Ku70/80 heterodimer followed by 
the DNA-PK catalytic subunit. Depending on the nature of the break, it may then be further 
processed by a combination of polymerases or helicases prior to final ligation of the break 
ends by the Ligase IV-XRCC4 complex, catalysed by XLF. 2. Homologous Recombination 
begins with the binding of the Mre11-Rad50-NBS1 complex to the break ends. Mre11 
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performs short-range resection, followed by long range resection by Exo1 or 
DNA2/WRN/BLM to form long, 3’ ssDNA intermediates. RPA binds the long ssDNA tracts 
formed by resection and Rad51 is loaded onto the ssDNA, assisted by BRCA2 and associated 
proteins. The Rad51-bound DNA forms a synaptic filament which is able to perform a 
homology search, invading the sister chromatid and using it as a template for repair. Final 
repair products may then arise via formation of several intermediates 3. The ATM-kinase is 
an important signalling event activated by double-strand breaks and performs multiple 
regulatory functions including checkpoint activation, chromatin remodelling and 
transcriptional regulation. Please note that this diagram is a simplified schematic of the DSB 
repair process, and for a more in-depth review, the reader is referred to several excellent 
review articles cited in the text.  
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Figure 3 Barriers to Systemic siRNA Delivery There are several challenges to the efficient delivery of RNAi therapeutics to tumours following 
systemic administration of the drug into the circulation (left). RNAi delivery technologies have developed a variety of strategies to address 
these barriers (right).  
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Figure 4 Radiation therapy combined with nanoparticle delivery of RNAi to tumour 
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Radiotherapy delivered to a lung tumour (left panel) seen as an axial cross section with 
dosimetry.  Comparison between no radiosensitiser, small molecule radiosensitiser and a 
nanoparticle radiosensitiser. Graphs (right) illustrate concept of therapeutic ratio as a 
relationship between normal tissue complication probability (NTCP) and tumour control (TC) 
dose-response curves. Biodistribution of small molecule radiosensitisers to both tumour and 
normal tissue shift both TCP and NTCP curve not improving therapeutic ratio. 
Biodistribution of nanoparticle radiosensitiser preferentially to the tumour shifts TCP more 
than NTCP thereby widening the therapeutic window. 
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• RNA interference (RNAi) is an emerging therapy that can precisely suppress proteins in a 
tumour cell 
• Proteins involved in the detection and repair of DNA damage can be targeted by RNAi to 
sensitize cancers to radiotherapy 
• Newly developed delivery platforms are surmounting the obstacles to the clinical 
translation of RNAi 
 
